Peri-operative increase of oxygen delivery has been shown to reduce mortality in high-risk surgical patients. This study compares the effectiveness of dopexamine and dobutamine when used to increase cardiac output as part of a regimen to increase oxygen delivery. Sixteen surgical patients were randomly allocated to receive either dopexamine or dobutamine, which was increased to a stable dose defined as either oxygen delivery index >600 ml/minlm', or tachycardia >20% above baseline, other dysrhythmias or angina. At this "stable" dose there were significant increases in cardiac index (2.4 ± 0.2 vs 3. 7 ± 0.3 l/minlm') and oxygen delivery (380± 73 vs 579±40 ml/minlm') in the dopexamine group (P< 0.05); but not the dobutamine group. Five out of eight patients receiving dopexamine and three out of eight receiving dobutamine reached target oxygen delivery. Three dobutamine patients, but no dopexamine patients, had angina or dysrhythmias. In preoperative high-risk surgical patients, dopexamine can allow greater increases in oxygen delivery than dobutamine, due to cardiac effects that limit the dobutamine infusion rate.
hydrochloride. Dopexamine HCl and dobutamine HCl have different pharmacological actions and different spectrums of vascular response, but no direct comparison between the use of these agents in the perioperative period has been performed, This is particularly important as increased mortality has been seen when dobutamine HCl has been used in an attempt to increase oxygen consumption by increasing oxygen delivery in a general group of critically ill patients 7, Dobutamine Hel is a mixture of two isomers which stimulate cardiac (3\ adrenoreceptors and a and (32 adrenoreceptors 8 • In previous studies it has been shown to be an inotropic agent causing an increase in cardiac output and stroke volume with only a mild systemic vasodilation 9 • Dobutamine HCl has been investigated in patients with cardiac failure 91 \ septic shock l2 ,IJ and in the peri-operative period I., and its inotropic action has been confirmed. Dopexamine HCl, however, is a dopamine analogue with action at (32 adrenoreceptors and DAI receptors but only moderate activity at (3\ and DA2 receptors. Dopexamine possesses no direct a-adrenoreceptor activity, but noradrenaline reuptake is inhibited I', leading mainly to vasodilation with only mild inotropic effects 1617. Dopexamine H Cl has been investigated in patients with cardiac failure where it has been shown to cause peripheral vasodilation and increased cardiac index l ,, 19 .
The different pharmacological profile of dopexamine HCl and dobutamine HCl suggests that there may be important differences between these two drugs when used for the peri-operative manipulation of the cardiovascular system in high-risk surgical patients. We have compared the cardiovascular and oxygen transport effects of dobutamine HCl with those of dopexamine HCl, to answer the clinically relevant question of which agent is most suitable for increasing peri-operative oxygen delivery, in high-risk surgical patients.
METHOD
Sixteen high-risk surgical patients, defined as being at high-risk by previous studies l • 2 , who had given informed consent, were randomly allocated to receive either dopexamine HCl or dobutamine HCl to increase oxygen delivery preoperatively. The study was approved by our institutional ethics committee, and randomization was undertaken on a weekly schedule. Only patients with previously uncontrolled dysrhythmias were excluded from the study. The patients were admitted to the Intensive Care Unit (lCU) 12 to 24 hours prior to their operation and under local anaesthesia a pulmonary artery thermodilution catheter (93A-131-7F, Edwards Division, Baxter Healthcare Corp, Irvine, Calif) and radial arterial line (Abbocath-T 20G or 22G, Abbott Laboratories Ltd, North Chicago, Ill) were inserted; the ECG was recorded continuously. The patients' regular medication was continued until surgery. Patients receiving {3-blockers were not included in the study. The patients' height and weight were recorded for calculation of their body surface area.
Cardiorespiratory parameters
The following cardiorespiratory variables were recorded: heart rate (HR), mean arterial pressure (MAP), mean pulmonary arterial pressure (MPAP) and right atrial pressure (RA) and pulmonary artery occlusion pressure (PAOP). The cardiac output was measured by thermodilution by average of results of four 5 ml injectates of cold (6 to 12 QC) 5% dextrose (Supermon 7210, Kontron Instruments, Milan, Italy), and cardiac index (Cl), systemic vascular resistance index (SVRI) and pulmonary vascular resistance index (PVRI) were derived using standard formulae and the body surface area. Arterial (Sa02) and mixed venous (SV02) oxygen saturations were measured (IL482 Cooximeter, Instrumentation Laboratories, Lexington, Mass) from samples drawn simultaneously, the haemoglobin (Hb) concentration in arterial blood was recorded. Oxygen delivery index (00 2 1), oxygen consumption index (V0 2 1) and oxygen extraction ratio Preoperative phase Initial cardiorespiratory data were obtained and intravenous modified fluid gelatin solution (Gelofusine, Consolidated Chemicals Ltd, Wrexham, England) was administered to obtain a PAOP of 12-15 mmHg. "Baseline" cardiorespiratory values were taken as those after fluid administration and prior to dopexamine or dobutamine infusion. Preoperatively the target for 00 2 1 was to equal or exceed 600 mllmin/m220. If this 00 2 1 was not achieved with intravenous fluid then dopexamine HCl or dobutamine HCI was started intravenously depending on the patient's randomization. During this phase PAOP was maintained at 12-15 mmHg by further administration of modified fluid gelatin solution. Dopexamine HCl was started at 0.5 p.g/kg/min and increased to 1.0, 2.0 and 4.0 p.g/kg/min each 20 minutes until a 00 2 1 of greater than 600 mllmin/m 2 had been achieved. Dobutamine HCl was started at 2 p.g/kg/min and increased to 5, 10 and 20 p.g/kg/min each 20 minutes until an oxygen delivery index of greater than 600 mllmin/m 2 had been achieved. The starting infusion rates were chosen because in unpublished pilot studies 1.0 p.g/kg/min of dopexamine HCI appeared to lead to similar cardiovascular effects as 5.0 p.g/kg/min of dobutamine HC!. The dose titrations were limited by the occurrence of cardiac side-effects, or an achievement of a 00 2 1 of greater than 600 mllmin/m 2 ; if these occurred the infusion rate of the dobutamine or dopexamine was reduced to the previous infusion increment and this was termed the "stable dose". Cardiac side-effects were defined for the purposes of the study as an increase in HR greater than 20070 above baseline, significant ST depression on the ECG, anginal chest pain or clinically important dysrhythmia such as the onset of atrial fibrillation, other supraventricular tachycardia, ventricular tachycardia, multifocal ventricular ectopic beats, or greater than 10 ventricular ectopic beats per minute. At the end-point of dose titration cardiorespiratory values were recorded at the maximum stable dose of the dopexamine or dobutamine.
Statistical analysis
Results are presented as mean ± SEM. Percentage changes in the measured parameters were calculated from baseline (after fluid administration) to the values at the highest stable dose of dopexamine or dobutamine. Both the percentage changes and the absolute values of the parameters recorded were compared by Student's t-test between the dopexamine and the dobutamine group. Paired Student's t-tests were used to compare the oxygen delivery index, cardiac index, oxygen extraction ratio and oxygen consumption index at baseline and after a stable dose of dopexamine or dobutamine had been achieved for the patients receiving either dopexamine or dobutamine. P<0.05 was taken as significant, and Bonferroni's method was used to correct for mUltiple comparisons.
RESULTS
Sixteen patients were admitted to the study. In the dopexamine group, the mean age was 69 ± 3 years (range 60-85) and in the dobutamine group was 71 ±2 years (range 62-81) ( Table 1 ). Initial measurement of haemodynamic parameters was made in all patients on admission to the IeU and after infusion of fluid to attain a PAOP of 12 to 15 mmHg ("Baseline"). There were no statistical differences in these values between the two groups either at admission or at baseline, although cardiac index and oxygen delivery index were lower in the dopexamine group compared to the dobutamine group (Table 2 ). There were no differences in the volumes of modified fluid gelatin solution administered to the two groups, either prior to starting the inotrope infusion, 512±83 ml for the dopexamine group and 650±144 ml for the dobutamine group, or, during the inotrope infusion, 146 ± 33 ml for the dopexamine group and 125 ± 33 ml for the dobutamine group.
In no patient was D0 2 1 able to be increased to greater than 600 mllmin/m 2 by intravenous fluids alone. Therefore all required infusion of either dopexamine Hel or dobutamine He\. Details of the titration of dopexamine and dobutamine are shown in Figure 1 .
Of the eight patients receiving dopexamine, five reached the target oxygen delivery index of 600 mllmin/m2, the other three being limited in the dose titration by a rise in heart rate of greater than 20070 above baseline.
No patient receiving dopexamine HCI developed significant dysrhythmic cardiac events, and none developed angina. Only three of the patients receiving dobutamine reached the target of 600 mllmin/m2, two of the others had their dobutamine titration limited by a rise in heart rate of greater than 20070 above baseline and the other three had significant angina or dysrhythmic cardiac events that required the dose of dobutamine to be reduced. Of particular note, in three of the patients who received dobutamine HCI, the oxygen delivery index fell when the dobutamine HCI was started. Figure 2 shows the percentage changes in various cardiorespiratory parameters for the patients receiving dopexamine and dobutamine. The increase in cardiac index, oxygen delivery index and stroke volume index was significantly greater with dopexamine than dobutamine, and the decrease in systemic vascular resistance index was significantly greater with dopexamine than dobutamine. None of the other differences reached significance. The actual change in cardiac index, oxygen delivery index and oxygen extraction ratio were significant, compared with baseline, for the patients receiving dopexamine ( Table  2) while none of these oxygen transport parameters showed significant changes with dobutamine infusion.
DISCUSSION
Over the last ten years the results of a number of randomized, controlled studies have been published which have investigated the role of "goal-directed" therapy, whereby critically ill or high-risk surgical patients have been treated to achieve specific cardiovascular values ("goals"), during some stage of their illness, often around the time of operation. Although most studies have shown some benefit from this approach, in a recent study where dobutamine was used to increase cardiac output, there was an increased mortality in the treatment group7. There are a number of problems in comparing the published studies, including differences in the type of patients studied, differences in the timing of treatment during the illness and differences in the drugs used. It wa~ in an effort to address this last point that this study was undertaken.
Four groups of patients have been included in studies of "goal-directed" therapy: patients undergoing surgery, patients with trauma, patients with sepsis, and general groups of patients who are critically ill. Studies on peri-operative patients have all shown an improved outcome in the treatment arm of the studyI-J, 6 . In studies of high-risk peri-operative patients, Boyd and colleagues', and Shoemaker et aF, showed significant reduction in postoperative mortality. Earlier, Schultz et al had shown significant reduction in mortality in patients undergoing operation for fractured neck of femur, but the treatment used in this study is not absolutely clear3. In a study of patients undergoing vascular surgery, Berlauk and colleagues 6 showed a reduction in peri-and postoperative cardiac events, but the reduction in mortality did not reach statistical significance. Studies of trauma patients have shown reduced post-trauma organ failure 5 , and improved survival in elderly patients'.
Less convincing results have been achieved in the studies of those patients who have proven sepsis. Edwards et aF' showed improved outcome in patients with septic shock compared with historical controls, and Tuchschmidt and colleagues 22 demonstrated improved survival in the group treated with "goaldirected" therapy, but this did not reach statistical significance. In a more recent study examining a heterogeneous group of critically ill patients, Hayes and colleagues 7 showed a higher mortality in patients in whom "goal-directed" therapy was undertaken. Their study differs from those so far described, particularly those on peri-operative patients, in so much as the patients were admitted to the study at a later stage of their illness, once complications had developed. Furthermore, the investigators tried to attain the goals for cardiac index, oxygen delivery and oxygen consumption, suggested by Shoemaker et aF, and this required high infusion rates of dobutamine HCl. The control group was also treated to elevate cardiac output if this was below 2.8 IImin/m2, showing that they too were treated in a goal-directed fashion, although the goals were different and lower rates of dobutamine HCl infusion were required. This was a well conducted study and is important because the differences in patients, study design, and drugs used might start to point the way to identifying which patients may benefit from "goal-directed" therapy, and also which drugs and which goals should be used.
Many of the patients in the groups that appear to benefit from this type of proactive management will be elderly with coexisting clinical conditions. In particular they are likely to have a high incidence of cardiovascular disease, and it is therefore essential to avoid proactive treatment which is itself harmful. The results of the current study show that it is possible to achieve a significantly greater increase in oxygen delivery with dopexamine HCl than dobutamine HCl. The difference and apparent poor performance of dobutamine HCl is largely a result of the number of patients in the dobutamine HCl group that had their titration of dobutamine HCllimited by cardiac sideeffects. Only three patients reached an oxygen delivery index of 600 mllmin/m 2 in the dobutamine HCl group compared with five in the dopexamine HCl group. No patient in the dopexamine HCl group needed to have the dopexamine HCl dose reduced because of the occurrence of cardiac dysrhythmias, whereas three patients in the dobutamine HCl group needed to have the dobutamine HCl reduced after sustaining clinically significant tachycardia or angina. The remaining patients-three in the dopexamine HCl group and two in the dobutamine HCl group-had to have the inotrope dosage limited by a rise in heart rate above 20070 of the baseline value.
There are a number of studies that compare the effects of dopexamine HCl and dobutamine HCl in humans. It is difficult to compare the other ~tudies with this one owing to differences in age and diagnosis. Mousedale et al compared the effects of dopexamine HCl and dobutamine HCl at apparently matched doses on heart rate, blood pressure and renal parameters in young, healthy volunteers and showed a marked tachycardia with dopexamine HCFJ. This is opposite to the findings in our study but is perhaps explained by our careful attention to maintaining cardiac pre-load and intravascular fluid status. In view of the vasodilator properties of both dopexamine HCl and dobutamine HC1, a reflex tachycardia is expected if ventricular filling pressures are not maintained. There may also be differences between the responses of normal volunteers and patients with pre-existing cardiac disease 24 ,2' which might partly explain the apparent discrepancy.
Jaski et al compared dopexamine HCl and dobutamine HCl in ten patients with cardiac failure, and demonstrated an improvement in cardiac function with both agents 26 • However, their patients only had a mean age of 53 years and they exluded patients with preexisting angina. Baumann et al'9 showed that both dopexamine HCl and dobutamine HCl improved cardiac function in a study of 33 patients with cardiac failure who had a mean age 60 years. In their study, however, patients known to have had cardiac dysrhythmias were excluded. There appeared to be little to differentiate the two agents except a greater vasodilator effect with dopexamine HCl. The patients specifically excluded by these study protocols, and the lower mean age, make the results difficult to compare with ours. Our study was designed as a clinically based study of "goal-directed" therapy for high-risk surgical patients and as such the only specific cardiac exclusion criteria were pre-existing, uncontrolled cardiac dysrhythmias. These differences in the patients studied might explain the apparent superiority of dopexamine HCI for increasing cardiac output without side-effects.
The limiting tachycardia and dysrhythmias that we saw in our study in the patient group receiving dobutamine HCI do not appear to have been reported before. It is noteworthy, however, that Shoemaket et al were unable to complete a planned study using dobutamine HCI to increase cardiac output as 20070 of their patients developed a tachycardia of 140 beats/ minl4. Even at a dose of 7.5 j.tg/kg/min the mean increase in heart rate from baseline was 20070 14 . It is possible that the high rate of cardiac side-effects seen with dobutamine HCI in our study may have been reduced if the infusion increments had been smaller, although at the lower doses it appears unlikely that we would have been able to achieve our oxygen delivery goals.
Other studies have demonstrated an increase in myocardial oxygen consumption with dobutamine HCI infusion 27 ,28, and have shown non-homogeneous changes in coronary blood flow following infusion of dobutamine HCI, particularly in patients with coronary artery diseaselO. This effect of dobutamine HCl has been used recently to demonstrate myocardial ischemia as an alternative to exercise testing 29 . Dopexamine, on the other hand, does not appear to significantly increase myocardial oxygen consumption when given at a dose that will increase cardiac output 24 ,JO. It is also possible that dopexamine HCl has a specific antidysrhythmic effectJI. Fourteen of our 16 patients were having operations for peripheral vascular disease and the incidence of coronary disease was likely to be high, even if it was not symptomatic because of low exercise ability. The one patient who had anginal chest pain following infusion of dobutamine HCl, although suffering from a previous myocardial infarction, did not usually suffer from angina.
Because we were not able to achieve such a large increase in oxygen delivery with dobutamine HCI, it is difficult to compare the changes in other parameters in a meaningful way. It is, however, important to note that there was an 11070 change in heart rate in both groups of patients despite the fact that the mean oxygen Anaesthesia and Intensive Care, Vol. 23, No. 4, August, 1995 delivery index increased so much less in the dobutarnine HCI group. In the dobutamine HCI group the increase in cardiac output was mainly due to the increase in heart rate rather than increase in stroke volume and this has been found previously with dobutamine HCF9. In our study dopexamine HCI appears to have increased cardiac output and oxygen delivery by both vasodilatory and mild inotropic action, which confirms earlier work I8 , 19 . It is possible that if dobutamine HCI and a vasodilator had been used, similar results to those seen with dopexamine HCI may have been achieved, but the titration of two agents to achieve slightly different end-points will be much more complicated.
Our study compared a fixed initial infusion and subsequent increase of dopexamine HCl with a similar regimen for dobutamine HCl. Although we had previously noted similar cardiovascular effects for 1.0 j.tg/kg/min of dopexamine HCI and 5.0 j.tg/kg/min of dobutamine HCI (Boyd, unpublished observations, 1989), different results may have been achieved if a lower starting infusion rate for dobutamine HCI had been used, or the subsequent increase of infusion rate had been undertaken in smaller steps.
In conclusion we have shown that in preoperative high-risk surgical patients, dopexamine HClleads to significantly greater increases in cardiac output and oxygen delivery than dobutamine HCl. The lack of effect of dobutamine HCI is largely due to the cardiac side-effects that limited the infusion rate. Although a study of differences in outcome is required, we currently suggest that dopexamine HCl rather than dobutamine HCI should be used preoperatively for increasing oxygen delivery due to its greater effectiveness and lower incidence of cardiac side-effects.
